SCHEDULE: RA Capital Divests Entire Dyne Therapeutics Stake

RA Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Dyne Therapeutics, Inc., holding 0.0% of common stock as of September 30, 2025.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their holdings in Dyne Therapeutics, Inc.
• As of September 30, 2025, the Reporting Persons beneficially own 0.00 shares of Dyne Therapeutics, Inc. common stock.
• This represents 0.0% of the total class of securities.
• The filing indicates a complete divestment of all previously reported beneficial ownership in Dyne Therapeutics by these entities and individuals.

Sentiment

Score: 3

Explanation: The complete divestment by a prominent institutional investor like RA Capital Management is generally perceived negatively, indicating a lack of confidence or a strategic shift away from the company. While not directly impacting operations, it can influence market sentiment and share price.

Negatives

• RA Capital Management, a prominent healthcare investor, has fully divested its stake in Dyne Therapeutics, Inc.
• This complete exit by a significant institutional investor could be interpreted negatively by the market, potentially signaling a lack of confidence or a strategic shift regarding Dyne Therapeutics' prospects.

Risks

• Potential negative market reaction to a significant institutional investor's complete divestment, which could lead to downward pressure on the company's stock price.
• Loss of a potentially influential shareholder and their associated expertise or support for the company.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

RA Capital Management is a well-known investor in the life sciences and healthcare sectors. Their complete exit from Dyne Therapeutics could be viewed in the context of their broader portfolio management strategy or specific views on Dyne's pipeline, clinical progress, or market position within the competitive biotechnology industry.

Stakeholder Impact

• Shareholders may react negatively to the news of a major institutional investor's complete exit, potentially leading to downward pressure on the stock price.
• Company management could face increased scrutiny regarding the company's prospects or strategy that may have contributed to the divestment.

Key Dates

Recommendation

The complete divestment by a significant institutional investor like RA Capital Management suggests a loss of confidence or a strategic decision to exit the position. This action, especially from a specialized healthcare fund, could signal underlying concerns about Dyne Therapeutics' future prospects, making a 'sell' recommendation prudent for investors who might interpret this as a negative signal and anticipate potential downward pressure on the stock.

Keywords

Dyne Therapeutics, RA Capital Management, Schedule 13G, Divestment, Institutional Ownership, Biotechnology, Healthcare Investment, Common Stock